Clinical trial
Nivolumab Plus Weekly Carboplatin and Paclitaxel as Induction in Resectable Locally Advanced Head and Neck Cancer
NCT03342911 is registered in ClinicalTrials.gov with Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Nivolumab Plus Weekly Carboplatin and Paclitaxel as Induction in Resectable Locally Advanced Head and Neck Cancer
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 13, 2017
- Completion date
- October 6, 2020
- Enrollment
- 34 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
name human papillomavirus positive oropharyngeal squamous cell carcinoma, stage ii oropharyngeal squamous cell carcinoma, stage iii hypopharyngeal squamous cell carcinoma, stage iii laryngeal squamous cell carcinoma, stage iii oral cavity squamous cell carcinoma, stage iii oropharyngeal squamous cell carcinoma, stage iv hypopharyngeal squamous cell carcinoma, stage iv laryngeal squamous cell carcinoma, stage iv oral cavity squamous cell carcinoma, stage iv oropharyngeal squamous cell carcinoma, stage iva hypopharyngeal squamous cell carcinoma, stage iva laryngeal squamous cell carcinoma, stage iva oral cavity squamous cell carcinoma, stage iva oropharyngeal squamous cell carcinoma, stage ivb hypopharyngeal squamous cell carcinoma, stage ivb laryngeal squamous cell carcinoma, stage ivb oral cavity squamous cell carcinoma, stage ivb oropharyngeal squamous cell carcinoma, stage ivc hypopharyngeal squamous cell carcinoma, stage ivc laryngeal squamous cell carcinoma, stage ivc oral cavity squamous cell carcinoma, stage ivc oropharyngeal squamous cell carcinoma